stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Total debt
10x Genomics's total debt at the end of fiscal 2022 was $95.0M, up 15.9% from $82.0M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $98.0M. Over the past ten years it has ranged from $29.7M (fiscal 2018) to $169.0M (fiscal 2017); the current reading is higher than 83% of that period. 10x Genomics ranks 40th of 147 Medical Devices companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $95.0M | 15.85% |
| FY2021 | $82.0M | 30.16% |
| FY2020 | $63.0M | 111.99% |
| FY2019 | $29.7M | 0.14% |
| FY2018 | $29.7M | (82.44%) |
| FY2017 | $169.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $98.0M | (1.01%) |
| Jun 2023 | $99.0M | (2.94%) |
| Mar 2023 | $102.0M | 7.37% |
| Dec 2022 | $95.0M | (1.04%) |
| 13 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $3.2B |
| BRKR Bruker Corporation compare | $1.7B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $1.2B |
| BIO Bio-Rad Laboratories, Inc. compare | $1.2B |
| HAE Haemonetics Corporation compare | $1.1B |
| PODD Insulet Corporation compare | $962.1M |
| GMED Globus Medical, Inc. compare | $443.4M |
| TXG 10x Genomics | $98.0M |
| PEN Penumbra, Inc. compare | $19.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement